World Cancer Liquid Biopsy Market 2017 - Insufficient Demonstrated Clinical Utility to Slow Adoption by Oncologists

DUBLIN, November 15, 2017 /PRNewswire/ --

The "Cancer Liquid Biopsy Market Assessment" report has been added to Research and Markets' offering.

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy contains markets for the following:

• Breast Cancer Liquid Biopsy Market
  
• Colorectal Cancer Liquid Biopsy Market
• Lung Cancer Liquid Biopsy Market
  
• Ovarian Cancer Liquid Biopsy Market
  
• Pancreatic Cancer Liquid Biopsy Market
• Other Cancer Liquid Biopsy Market

Top Ten Companies in the Market:

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging.

Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.